Contact UsEmployment Ops











Founded in 2007 and headquartered in Gaithersburg, MD, Amplimmune is focused on developing novel therapeutics through immune system modulation. With its strong product-based focus, Amplimmune has rapidly developed three biologic product candidates:

AMP-224 is in Phase 1b trials in cancer in collaboration with GlaxoSmithKline

AMP-110 for autoimmune diseases in partnership with Daiichi Sankyo

AMP-514 for cancer and infectious diseases

By leveraging its GMP manufacturing capabilities and in depth knowledge of immunomodulatory pathways, Amplimmune is developing novel immunomodulatory molecules with broad spectrum applications in the treatment of cancer, autoimmunity, transplantation and infectious diseases. Working closely with key academic and industry collaborators, Amplimmune has created a platform of novel reagents, models, know-how and intellectual property to further develop a unique product pipeline including novel biomarkers, ligands and receptors.


  Copyright ©2007 Amplimmune, Inc.